<DOC>
	<DOC>NCT01203072</DOC>
	<brief_summary>The objective of this study is to assess the efficacy, safety and dose-response relationship of DU-176b compared with placebo for the prevention of venous thromboembolism in patients after elective total knee arthroplasty.</brief_summary>
	<brief_title>A Phase 2b Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty</brief_title>
	<detailed_description />
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Edoxaban</mesh_term>
	<criteria>Patients undergoing unilateral total knee arthroplasty risks of hemorrhage thromboembolic risks weight less than 40 kg pregnant, suspect pregnancy, or subjects who want to become pregnant</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>84 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>prevention</keyword>
	<keyword>venous thromboembolism</keyword>
	<keyword>edoxaban</keyword>
	<keyword>factor Xa</keyword>
</DOC>